Recent advances in management of the HIV/HCV coinfected patient.

TitleRecent advances in management of the HIV/HCV coinfected patient.
Publication TypeJournal Article
Year of Publication2015
AuthorsBednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD
JournalFuture Virol
Volume10
Issue8
Pagination981-997
Date Published2015
ISSN1746-0794
Abstract

Chronic hepatitis C virus (HCV) is a global epidemic, affecting approximately 150 million individuals throughout the world. The implications of HCV infection have been magnified in those who are infected with both HCV and the HIV as liver disease progression, liver failure and liver-related death are increased, particularly in those without well-controlled HIV disease. The development of direct-acting antiviral agents for HCV that allow shorter treatment periods with increased efficacy and decreased adverse events have greatly changed the outlook for HCV-infected individuals. With these advancements, growing treatment options for the coinfected population have also come. This review will address pharmacotherapy issues in the HIV/HCV coinfected population.

DOI10.2217/fvl.15.64
Alternate JournalFuture Virol
PubMed ID26877758
PubMed Central IDPMC4751983
Grant ListK23 AI108355 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI069511 / AI / NIAID NIH HHS / United States
UM1 AI106701 / AI / NIAID NIH HHS / United States